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A
	 Are	inhaled	steroids	effective	
for	a	postviral	cough?	
	 No.	 Inhaled	 corticosteroids	 (ICS)
	 don’t	 improve	 postviral	 cough	
in	 adults	 with	 subacute	 (3-8	 weeks)	 or	
chronic	 (>8	 weeks)	 cough,	 adolescents	
with	a	history	of	asthma	but	without	recent	
asthma	activity,	or	children	with	a	history	
of	episodic	viral	wheezing	without	asthma	
(strength	 of	 recommendation	 [SOR]:	 B,	
preponderance	of	 small	 randomized	con-
trolled	trials	[RCTs]).
evidence summary
A	systematic	 review	of	7	RCTs	with	a	 total	of	
477	 adults	 that	 examined	 the	 efficacy	 of	 ICS	
compared	with	placebo	 for	 treating	subacute	
(3-8	 weeks)	 and	 chronic	 (>8	 weeks)	 cough	
found	 inconsistent,	 but	 mostly	 negative	 re-
sults.1	Most	trials	combined	patients	with	non-
specific	subacute	and	chronic	cough.	
The	 evaluated	 steroids	 included	 beclo-
methasone,	 budesonide,	 fluticasone,	 and	
mometasone;	daily	“budesonide	equivalent”	
doses	ranged	from	320	mcg	to	1600	mcg.	Six	
of	 the	7	 trials	 found	that	 ICS	didn’t	 improve	
cough.	The	seventh	didn’t	treat	patients	with	
postviral	 cough.	 The	 authors	 of	 the	 review	
couldn’t	pool	data	because	of	heterogeneity.
Steroids don’t affect  
methacholine challenge in teens
A	 double-blind,	 placebo-controlled	 RCT	 of	
56	adolescents	found	that	giving	ICS	after	vi-
ral	upper	respiratory	infection	didn’t	change	
the	 methacholine	 dosing	 necessary	 to	 pro-
duce	a	20%	reduction	in	the	forced	expiratory	
volume	 in	 one	 second	 (FEV1).2	 Investigators	
included	patients	if	they	had	a	previous	diag-
nosis	of	asthma	but	no	use	of	asthma	medi-
cations	 in	 2	 years,	 a	 baseline	 FEV1	 greater	
than	 70%	 of	 predicted,	 and	 a	 concentration	
of	methacholine	 that	produced	a	20%	fall	 in	
FEV1	less	than	8	mg/mL.	
They	 randomized	 patients	 to	 inhaled	
budesonide	(2	200-mcg	puffs	bid)	or	placebo	
(2	500-mcg	puffs	micronized	lactose	bid).	Pa-
tients	underwent	spirometry	and	methacho-
line	challenge	testing	every	3	months	over	a	
9-month	 period.	The	 groups	 didn’t	 differ	 in	
bronchial	hyperresponsiveness	or	FEV1.
Lower respiratory symptoms don’t  
respond to ICS in nonasthmatic children
A	 systematic	 review	 of	 5	 RCTs	 with	 a	 total	
of	 339	 patients	 found	 that	 in	 4	 of	 the	 5,	 ICS	
didn’t	 improve	 lower	 respiratory	 symptoms	
in	 children	 with	 episodic	 viral	 wheeze	 and	
no	history	of	asthma.3	Investigators	evaluated	
ICS	 efficacy	 using	 lower	 respiratory	 symp-
tom	 scores	 (based	 primarily	 on	 cough	 and	
wheeze)	and	decreased	use	of	oral	steroids	or	
reduced	emergency	room	visits.	
Four	trials	found	no	benefit	from	ICS;	one	
trial	(52	children	with	viral-induced	wheeze)	
found	 that	 nebulized	 budesonide	 (400	 mg	
qid	for	2	days,	then	bid	for	7	days)	decreased	
respiratory	symptom	scores	(weighted	mean	
difference=	 -0.17;	 95%	 confidence	 interval,	
-0.34	 to	 -0.003)	 compared	with	 placebo.	 In-
vestigators	 didn’t	 assess	 cough	 separately	
from	wheezing,	however.					 													JFP	
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